Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft (PDX), Xenograft)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global oncology based in-vivo CRO market size was exhibited at USD 1.9 billion in 2022 and is projected to hit around USD 4.22 billion by 2032, growing at a CAGR of  8.3% during the forecast period 2023 to 2032.

Oncology Based In-vivo CRO Market Size

Key Pointers:

  • Solid tumors segment accounted for a significant revenue share of 46.11% in 2022. The increasing incidence of cancer across the globe and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
  • Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 8.10% during the forecast period
  • North America accounted for the largest share of 49.19% in 2022, with the major contributions from the U.S., thanks to promising funding available in the region. This has boosted the research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
  • Asia Pacific is anticipated to register the fastest CAGR growth during the forecast period, owing to many developed countries investing in Asia Pacific regions and owing to the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Oncology Based In-vivo CRO Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 2.06 Billion

Market Size by 2032

USD 4.22 Billion

Growth Rate from 2023 to 2032

CAGR of 8.3%

Base year

2022

Forecast period

2023 to 2032

Segments covered

Indication

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

Charles River Laboratory; ICON Plc; LabCorp; Eurofins Scientific; Taconic Biosciences; Crown Bioscience; Thermo Fisher Scientific Inc., Inc.; WuXi AppTec; EVOTEC; The Jackson Laboratory

 

The increasing frequency of outsourcing of R&D activities by major pharmaceutical companies to focus on their core competencies is a high-impact-rendering driver for market growth. Furthermore, the economic efficiency offered by CROs rather than conducting an in-house study is likely to boost their demand over the forecast period.

The oncology based in-vivo CRO activities were heavily disrupted in 2020 owing to the repercussions of the COVID-19 pandemic. Several clinical trials were delayed owing to the ongoing pandemic. Cancer patients are vulnerable to COVID and are at high risk for contracting severe consequences from the disease. According to the International Agency for Research on Cancer (IARC), the global cancer burden was 19.3 million cases in 2020.

The challenge for healthcare providers was to limit the exposure of their patients and patients’ caregivers to COVID patients as well as asymptomatic carriers while continuing to ensure access to clinical trials. However, the future seems promising for the market with the emergence of telehealth and virtual clinical trials. Such technologies allow CRO activities while ensuring the safety of cancer patients. Furthermore, regulatory bodies such as the U.S. FDA have issued guidance and developed new policies to cope with the current scenario and solve the problem of bottlenecked clinical trials.

The present business scenario is witnessing rapid changes in the marketplace and consumer preferences are pushing the players to innovate and generate better-performing products at a faster rate to sustain. CROs have developed their products and services such that they help manufacturers in gaining momentum with their R&D processes and overcome any hurdles that they may face.

Owing to their proficiency and years of experience in the business, CROs perform the given tasks at an exceptionally fast speed. According to a survey conducted by Tufts Center for the Study of Drug Development (CSDD), among the top management of the major pharmaceutical companies, more than 75.0% of executives said that CROs are more time-efficient in comparison to the internal teams, thereby increasing the need for outsourcing.

Pharmaceutical organizations are increasingly outsourcing R&D activities to CROs to stay competitive and flexible in the world of growing knowledge, gradually sophisticated technologies, and an unstable economic environment. The tasks that companies prefer to outsource include a wide range of activities from basic research to late-stage development such as target validation, hit exploration, and lead optimization, genetic engineering, assay development safety, and efficacy tests in animal models as well as clinical trials involving humans.

North America dominated the oncology based in-vivo CRO market and accounted for the largest revenue share of 49.19% in 2022. This can be attributed to the presence of technologically advanced CROs present in this region. The U.S. has the highest per capita healthcare spending and the availability of funding and grants from government organizations such as the National Institute of Health (NIH) fosters research activities. The trend for reducing the R&D cost level is most common in major life sciences companies. Clinical trial sponsors are facing huge pressure owing to the increasing complexity of the research methodology to reduce time and cost. The increasing R&D activities and the need to reduce the overall trial expenditure are expected to drive the need for CROs in North America.

Some of the prominent players in the Oncology Based In-vivo CRO Market include:

  • Charles River Laboratory
  • ICON Plc
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific
  • Taconic Biosciences
  • Crown Bioscience
  • LabCorp
  • WuXi AppTec
  • EVOTEC
  • The Jackson Laboratory

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Oncology Based In-vivo CRO market.

By Indication 

  • Blood cancer
    • Syngeneic model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Solid tumors
    • Syngeneic model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Others
    • Syngeneic model
    • Patient Derived Xenograft (PDX)
    • Xenograft

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global oncology based in-vivo CRO market size was exhibited at USD 1.9 billion in 2022 and is projected to hit around USD 4.22 billion by 2032

The global oncology based in-vivo contract research organization market is expected to grow at a compound annual growth rate of 8.3% from 2023 to 2032

North America dominated the oncology based in-vivo contract research organization market with a share of 46.11% in 2022. This is attributable to the increasing frequency of outsourcing R&D activities by the major pharmaceutical companies in order to focus on their core competencies is the vital impact rendering driver.

Some key players operating in the oncology based in-vivo contract research organization market include Crown Bioscience, Charles River Laboratory, ICON Plc., Eurofins Scientific, Taconic Biosciences, LabCorp, EVOTEC, The Jackson Laboratory, and Wuxi AppTec. Other players operating in this space are MI Bioresearch, Inc., Living Tumor Laboratory, Champion Oncology, Inc., and Xentech.

Chapter 1 Research Methodology
                  1.1 Market Segmentation & Scope
                      1.1.1 Regional Scope
                      1.1.2 Estimates and Forecast Timeline
                  1.2 Research Methodology
                  1.3 Information Procurement
                      1.3.1 Purchased Database
                      1.3.2 Nova one advisor’s Internal Database
                      1.3.3 Secondary Sources
                      1.3.4 Primary Research
                      1.3.5 Details of Primary Research
                  1.4 Information or Data Analysis
                      1.4.1 Data Analysis Models
                  1.5 Market Formulation & Validation
                  1.6 Model Details
                      1.6.1 Commodity Flow Analysis (Model 1)
                      1.6.2 Volume Price Analysis (Model 2)
                  1.7 List of Secondary Sources
                  1.8 List of Primary Sources
                  1.9 List of Abbreviations
                  1.10 Objectives
Chapter 2 Executive Summary
                  2.1 Market Outlook
Chapter 3 Oncology-Based In-vivo CRO Market: Variables, Trends, & Scope
                  3.1 Segment Outlook
                  3.2 Market Dynamics
                      3.2.1 Market Driver Analysis
                          3.2.1.1 Accelerating the time to market
                          3.2.1.2 Economic efficiency
                          3.2.1.3 Increasing mergers and collaborations
                          3.2.1.4 Increasing outsourcing of R&D Activities
                      3.2.2 Market Restraint Analysis
                          3.2.2.1 Quality issues with CRO
                          3.2.2.2 Presence of suitable alternative
                  3.3 Oncology In-vivo CRO Market Analysis Tools
                      3.3.1 Porter’s Five Forces Analysis
                      3.3.2 PESTEL Analysis
Chapter 4 Oncology-Based in-vivo CRO Market: Indication Estimates & Trend Analysis
                  4.1 Oncology-Based in-vivo CRO Market: Indication Movement Analysis
                  4.2 Blood cancer
                      4.2.1 Blood cancer market estimates and forecasts, 2020 - 2032
                          4.2.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2020 - 2032
                          4.2.1.2 PDX-based solid tumor market estimates and forecasts, 2020 - 2032
                          4.2.1.3 Xenograft-based solid tumor market estimates and forecasts, 2020 - 2032
                  4.3 Solid tumors
                      4.3.1 Solid tumors market estimates and forecasts, 2020 - 2032
                          4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2020 - 2032
                          4.3.1.2 PDX-based solid tumor market estimates and forecasts, 2020 - 2032
                          4.3.1.3 Xenograft-based solid tumor market estimates and forecasts, 2020 - 2032
                  4.4 Others
                      4.4.1 Other market estimates and forecasts, 2020 - 2032
                          4.4.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2020 - 2032
                          4.4.1.2 PDX-based solid tumor market estimates and forecasts, 2020 - 2032
                          4.4.1.3 Xenograft-based solid tumor market estimates and forecasts, 2020 - 2032
Chapter 5 Oncology-Based in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication
                  5.1 Oncology-Based in-vivo CRO Market Share by Region, 2023 & 2032
                  5.2 North America
                      5.2.1 North America Oncology-Based in-vivo CRO market estimates and forecasts, 2020 - 2032
                      5.2.2 U.S.
                          5.2.2.1 U.S. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.2.3 Canada
                          5.2.3.1 Canada Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                  5.3 Europe
                      5.3.1 Europe Oncology-Based in-vivo CRO market estimates and forecasts, 2020 - 2032
                      5.3.2 U.K.
                          5.3.2.1 U.K. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.3 Germany
                          5.3.3.1 Germany Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.4 France
                          5.3.4.1 France Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.5 Italy
                          5.3.5.1 Italy Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.6 Spain
                          5.3.6.1 Spain Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.7 Norway
                          5.3.7.1 Norway Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.8 Sweden
                          5.3.8.1 Sweden Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.3.9 Denmark
                          5.3.9.1 Denmark Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                  5.4 Asia Pacific
                      5.4.1 Asia Pacific Oncology-Based in-vivo CRO market estimates and forecasts, 2020 - 2032
                      5.4.2 Japan
                          5.4.2.1 Japan Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.4.3 China
                          5.4.3.1 China Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.4.4 India
                          5.4.4.1 India Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.4.5 Australia
                          5.4.5.1 Australia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.4.6 Thailand
                          5.4.6.1 Thailand Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.4.7 South Korea
                          5.4.7.1 South Korea Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                  5.5 Latin America
                      5.5.1 Latin America Oncology-Based in-vivo CRO market estimates and forecasts, 2020 - 2032
                      5.5.2 Brazil
                          5.5.2.1 Brazil Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.5.3 Argentina
                          5.5.3.1 Argentina Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.5.4 Mexico
                          5.5.4.1 Mexico Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                  5.6 MEA
                      5.6.1 MEA Oncology-Based in-vivo CRO market estimates and forecasts, 2020 - 2032
                      5.6.2 South Africa
                          5.6.2.1 South Africa Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.6.3 Saudi Arabia
                          5.6.3.1 Saudi Arabia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.6.4 UAE
                          5.6.4.1 UAE Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
                      5.6.5 Kuwait
                          5.6.5.1 Kuwait Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2020 - 2032
Chapter 6 Competitive Landscape
                  6.1 Strategy Framework
                  6.2 Company Profiles
                      6.2.1 Charles River Laboratory (CRL)
                          6.2.1.1 Company overview
                          6.2.1.2 Financial performance
                          6.2.1.3 Product benchmarking
                          6.2.1.4 Strategic initiatives
                      6.2.2 ICON Plc
                          6.2.2.1 Company overview
                          6.2.2.2 Financial performance
                          6.2.2.3 Product benchmarking
                          6.2.2.4 Strategic initiatives
                      6.2.3 Thermo Fisher Scientific Inc.
                          6.2.3.1 Company overview
                          6.2.3.2 Financial performance
                          6.2.3.3 Service benchmarking
                          6.2.3.4 Strategic initiatives
                      6.2.4 Eurofins Scientific
                          6.2.4.1 Company overview
                          6.2.4.2 Financial performance
                          6.2.4.3 Product benchmarking
                          6.2.4.4 Strategic initiatives
                      6.2.5 Taconic Biosciences
                          6.2.5.1 Company overview
                          6.2.5.2 Financial performance
                          6.2.5.4 Product benchmarking
                          6.2.5.5 Strategic initiatives
                      6.2.6 Crown Bioscience
                          6.2.6.1 Company overview
                          6.2.6.2 Financial performance
                          6.2.6.3 Product benchmarking
                          6.2.6.4 Strategic initiatives
                      6.2.7 Lab Corp
                          6.2.7.1 Company overview
                          6.2.7.2 Financial performance
                          6.2.7.3 Product benchmarking
                          6.2.7.4 Strategic initiatives
                      6.2.8 WuXi AppTec
                          6.2.8.1 Company overview
                          6.2.8.2 Financial performance
                          6.2.8.4 Product benchmarking
                          6.2.8.5 Strategic Initiatives
                      6.2.9 EVOTEC
                          6.2.9.1 Company overview
                          6.2.9.2 Financial performance
                          6.2.9.3 Product benchmarking
                          6.2.9.4 Strategic initiatives
                      6.2.10 The Jackson Laboratory
                          6.2.10.1 Company overview
                          6.2.10.2 Financial performance
                          6.2.10.4 Product benchmarking
                          6.2.10.5 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert